James L. Kuhlen
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James L. Kuhlen.
PLOS ONE | 2016
Kimberly G. Blumenthal; Erica S. Shenoy; Mingshu Huang; James L. Kuhlen; Winston Ware; Robert A. Parker; Rochelle P. Walensky
Background Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection with mortality benefit from receipt of parenteral β-lactam therapy. A substantial portion of MSSA bacteremia patients report penicillin allergy, but infrequently have true allergy. Objective To determine the frequency and predictors of optimal and adequate therapy in patients with MSSA bacteremia. Design Retrospective cohort. Participants Adult inpatients with MSSA bacteremia, January 2009 through October 2013. Main Measures The primary measure was a trial of optimal therapy (OT), defined as ≥3 inpatient days or discharge on any first-line agents (nafcillin, oxacillin, cefazolin, or penicillin G, if susceptible). The secondary measure was completion of adequate therapy (AT), defined as ≥10 inpatient days or discharge on an agent appropriate for MSSA bacteremia. Data were electronically gathered with key variables manually validated through chart review. Log-binomial regression models were used to determine the frequency and predictors of outcomes. Key Results Of 456 patients, 346 (76%) received a trial of OT. Patients reporting penicillin allergy (13%) were less likely to receive OT trial than those without penicillin allergy (47% vs. 80%, p <0.001). Adjusting for other factors, penicillin allergy was the largest negative predictor of OT trial (RR 0.64 [0.49, 0.83]). Infectious Disease (ID) consultation was the largest positive predictor of OT trial across all patients (RR 1.34 [1.14, 1.57]). Allergy/Immunology consultation was the single most important predictor of OT trial among patients reporting penicillin allergy (RR 2.33 [1.44, 3.77]). Of 440 patients, 391 (89%) completed AT, with ID consultation the largest positive predictor of the outcome (RR 1.28 [1.15, 1.43]). Conclusions Nearly 25% of patients with MSSA bacteremia did not receive OT trial and about 10% did not receive AT completion. Reported penicillin allergy reduced, and ID consult increased, the likelihood of OT. Allergy evaluation, coupled with ID consultation, may improve outcomes in MSSA bacteremic patients.
The Journal of Allergy and Clinical Immunology: In Practice | 2016
James L. Kuhlen; Carlos A. Camargo; Diana S. Balekian; Kimberly G. Blumenthal; Autumn Guyer; Theresa Morris; Aidan A. Long; Aleena Banerji
BACKGROUND Hypersensitivity reactions (HSRs) during the perioperative period are unpredictable and can be life threatening. Prospective studies for the evaluation of perioperative HSRs are lacking, and data on causative agents vary between different studies. OBJECTIVE The objective of this study was to prospectively determine the success of a comprehensive allergy evaluation plan for patients with HSRs during anesthesia, including identification of a causative agent and outcomes during subsequent anesthesia exposure. METHODS All patients referred for a perioperative HSR between November 2013 and March 2015, from a Boston teaching hospital, were evaluated using a standardized protocol with skin testing (ST) within 6 months of HSR. Comprehensive allergy evaluation included collection of patient information, including characteristics of HSR during anesthesia. We reviewed the results of ST and/or test doses for all potential causative medications Event-related tryptase levels were reviewed when available. RESULTS Over 17 months, 25 patients completed the comprehensive allergy evaluation. Fifty-two percent (13 of 25) were female with a median age of 52 (interquartile range 43-66) years. The most frequently observed HSR systems were cutaneous (68%), cardiovascular (64%), and pulmonary (24%). A culprit drug, defined as a positive ST, was identified in 36% (9 of 25) of patients. The most common agent identified was cefazolin (6 of 9). After our comprehensive evaluation and management plan, 7 (7 of 8, 88%) patients tolerated subsequent anesthesia. CONCLUSIONS Cefazolin was the most commonly identified cause of a perioperative HSR in our study population. Skin testing patients within 6 months of a perioperative HSR may improve the odds of finding a positive result. Tolerance of subsequent anesthesia is generally achieved in patients undergoing our comprehensive evaluation.
Allergy and Asthma Proceedings | 2015
James L. Kuhlen; Aleena Banerji
This review on hereditary angioedema (HAE) focused on special topics regarding HAE in children, women of childbearing age, and the elderly. HAE is a rare autosomal dominant bradykinin-mediated disorder characterized by recurrent attacks of subcutaneous or submucosal swelling that usually affects the face, upper airway, extremities, gastrointestinal tract, or genitalia. These recurrent attacks cause significant morbidity and can be life threatening, especially when the swelling affects the airway. Our objective was to summarize the published data available on the disease epidemiology, pathophysiology, clinical presentation, on demand and prophylactic therapy, and focus on management considerations for these special patient populations. Unique aspects of HAE in women with regard to contraception, hormone replacement therapy, pregnancy, lactation, and menopause were also reviewed.
Open Forum Infectious Diseases | 2015
James L. Kuhlen; Kimberly G. Blumenthal; Caroline L. Sokol; Diana S. Balekian; Ana A. Weil; Christy A. Varughese; Erica S. Shenoy; Aleena Banerji
Validated skin testing is lacking for many drugs, including ceftaroline. The cross-reactivity between ceftaroline and other β-lactam antibiotics is unknown. We report a case of a pregnant patient with cystic fibrosis and multiple drug allergies who required ceftaroline for methicillin-resistant Staphylococcus aureus pneumonia and underwent an uncomplicated empiric desensitization procedure.
Clinical Infectious Diseases | 2018
Kimberly G. Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L. Kuhlen; Erica S. Shenoy
The Journal of Allergy and Clinical Immunology: In Practice | 2016
Kimberly G. Blumenthal; James L. Kuhlen; Ana A. Weil; Christy A. Varughese; David W. Kubiak; Aleena Banerji; Erica S. Shenoy
The Journal of Allergy and Clinical Immunology: In Practice | 2015
Iris M. Otani; James L. Kuhlen; Kimberly G. Blumenthal; Autumn Guyer; Aleena Banerji
Annals of Allergy Asthma & Immunology | 2014
James L. Kuhlen; Autumn Guyer; Tricia Morphew; Raffi Tachdjian; Aleena Banerji
The Journal of Allergy and Clinical Immunology | 2015
James L. Kuhlen; Aidan A. Long; Carlos A. Camargo; Aleena Banerji
Open Forum Infectious Diseases | 2015
Kimberly G. Blumenthal; James L. Kuhlen; Ana A. Weil; Christy A. Varughese; David W. Kubiak; Aleena Banerji; Erica S. Shenoy